Notícias e Atividades da Verrica Pharmaceuticals

Verrica Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Verrica Pharmaceuticals é uma empresa listada sob o símbolo VRCA (US).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Verrica Pharmaceuticals

• Jayson Rieger, Chief Executive Officer
• Sean Stalfort, Director
• Lawrence Eichenfield, Director

Recentes movimentos de executivos em Verrica Pharmaceuticals

• Gavin Corcoran, ingressou na Companhia como Director  (Notícia publicada em 4 de abril de 2025).
• Noah Rosenberg, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 28 de março de 2025).
• Gary Goldenberg, Director and Chief Medical Officer, deixou a Companhia  (Notícia publicada em 28 de março de 2025).

Clique aqui para ver outras movimentos em Verrica Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Verrica Pharmaceuticals.

Verrica Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Verrica Pharmaceuticals

• Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - Verrica Pharmaceuticals
• Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Verrica Pharmaceuticals
• Verrica Provides Business and Operational Update - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - Verrica Pharmaceuticals
• Verrica Announces Pricing of $42.0 Million Public Offering - Verrica Pharmaceuticals
• Press Releases - Verrica Pharmaceuticals
• Verrica Announces Proposed Public Offering - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - Verrica Pharmaceuticals
• Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Verrica Pharmaceuticals
• View more press releases Close

Redes sociais sobre Verrica Pharmaceuticals

• Verrica Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Verrica Pharmaceuticals na LinkedIn, Twitter e YouTube